Xiaoyun Lu

Allosterische Kinaseinhibitoren – Erwartungen und Chancen

Ke Ding, Xiaoyun Lu, J. B. Smaill, 2020 .

Allosterische Kinaseinhibitoren – Erwartungen und Chancen

Ke Ding, Xiaoyun Lu, J. B. Smaill, 2020, Angewandte Chemie.

Discovery of 6-Formylpyridyl Urea Derivatives as Potent Reversible-Covalent Fibroblast Growth Factor Receptor 4 Inhibitors with Improved Anti-Hepatocellular Carcinoma Activity.

J. Smaill, A. Patterson, Xiaojuan Chen, 2024, Journal of medicinal chemistry.

Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib

Xiaoyun Lu, Shuang Xiang, 2023, Acta pharmaceutica Sinica. B.

Discovery of the First Examples of Threonine Tyrosine Kinase PROTAC Degraders.

Yong Xu, Xiaoyun Lu, Ke Ding, 2022, Journal of medicinal chemistry.

Structure-Based Optimization of Pyrazinamide-Containing Macrocyclic Derivatives as Fms-like Tyrosine Kinase 3 (FLT3) Inhibitors to Overcome Clinical Mutations.

Zhang Zhang, Zhi-Min Zhang, Yang Zhou, 2024, ACS pharmacology & translational science.